Interested in Collegium Pharmaceutical Inc (COLL) Stock? Look at ADHD Portfolio

Collegium Pharmaceutical Inc (NASDAQ:COLL) is one of the best micro and small cap stocks to buy according to Jim Simons’ Renaissance Technologies. Analysts expect the stock to gain 57% over the next 12 months.

Interested in Collegium Pharmaceutical Inc (COLL) Stock? Look at ADHD Portfolio

On May 7, Collegium Pharmaceutical Inc (NASDAQ:COLL) reported Q1 2026 results that both increased from the prior year and exceeded the Street’s expectations. The management also highlighted plans to drive further growth, increase profitability, and improve shareholder returns.

Revenue rose 9% YoY to $193.5 million and topped the projected $187.4 million. Adjusted EPS of $1.76 rose from $1.49 a year ago and exceeded the anticipated $1.63. The quarter was buoyed by solid growth in the company’s ADHD franchise and continued strength in the pain management portfolio.

Collegium’s ADHD medicine Jornay PM was a standout performer in Q1, with its sales jumping 36% YoY. This growth was supported by market share expansion driven by increases in prescriptions and prescriber base. Collegium has moved to expand its ADHD portfolio with the acquisition of Azstarys. A market study found that 54% of healthcare providers surveyed plan to increase prescribing of Azstarys. Collegium expects Azstarys to contribute more than $50 million to H2 2026 revenue.

The company expects continued growth in Jornay PM sales for the remainder of the year. It anticipates this product to bring in between $190 million and $200 million in revenue in 2026, indicating a growth of around 31% YoY. To get there, Collegium plans to expand the drug’s subscriber base and increase its patient awareness.

Massachusetts-based Collegium Pharmaceutical Inc (NASDAQ:COLL) is a specialty drug company. It develops medications to treat complex medical conditions, and its portfolio includes ADHD medications and pain management drugs.

While we acknowledge the risk and potential of COLL as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than COLL and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 7 Best Small Cap Agriculture Stocks to Buy Now and 8 Best Gold Stocks Under $5.

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1